Note 3 - Merger with Old Cytocom - Pro Forma Information (Details) - Cleveland BioLabs, Inc. [Member] - USD ($)	3 Months Ended
Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 997,839	$ 836,686
Net loss	$ (7,757,210)	$ (5,965,956)

The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(3)
-URI https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463

Name:	us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration